2002
DOI: 10.1093/ndt/17.3.512
|View full text |Cite
|
Sign up to set email alerts
|

Transplant‐associated inflammatory breast disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
7
0

Year Published

2002
2002
2007
2007

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(7 citation statements)
references
References 10 publications
0
7
0
Order By: Relevance
“…Regression of FAs is possible after discontinuation of CsA, 12 or switching to alternative agents, such as tacrolimus (FK) or mycophenolate 13–15 . Although both CsA and FK are calcineurim inhibitors and have similar characteristics, the adverse effects and calcineurim phosphatase inhibitory profiles are different 13–15 .…”
Section: Discussionmentioning
confidence: 99%
See 4 more Smart Citations
“…Regression of FAs is possible after discontinuation of CsA, 12 or switching to alternative agents, such as tacrolimus (FK) or mycophenolate 13–15 . Although both CsA and FK are calcineurim inhibitors and have similar characteristics, the adverse effects and calcineurim phosphatase inhibitory profiles are different 13–15 .…”
Section: Discussionmentioning
confidence: 99%
“…5,10,11 Regression of FAs is possible after discontinuation of CsA, 12 or switching to alternative agents, such as tacrolimus (FK) or mycophenolate. [13][14][15] Although both CsA and FK are calcineurim inhibitors and have similar characteristics, the adverse effects and calcineurim phosphatase inhibitory profiles are different. [13][14][15] The conversion of immunosuppressive drugs is recommended for those patients who have a progressive reduction in renal function or other CsA adverse-effects like FAs.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations